Search

Your search keyword '"Gelderblom H"' showing total 46 results

Search Constraints

Start Over You searched for: Author "Gelderblom H" Remove constraint Author: "Gelderblom H" Language undetermined Remove constraint Language: undetermined
46 results on '"Gelderblom H"'

Search Results

1. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up

2. Genome-wide analyses of platinum-induced ototoxicity in childhood cancer patients: Results of GO-CAT and United Kingdom MAGIC consortia

3. Atrial fibrillation in cancer: thromboembolism and bleeding in daily practice

4. Meer regie nodig bij toegang tot medicatie vóór registratie

5. Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study

6. High-Dose Chemotherapy and Blood Autologous Stem-Cell Rescue Compared With Standard Chemotherapy in Localized High-Risk Ewing Sarcoma: Results of Euro-E.W.I.N.G.99 and Ewing-2008

7. Bone sarcomas: ESMO–EURACAN–GENTURIS–ERN PaedCan Clinical Practice Guideline for diagnosis, treatment and follow-up ?

8. Quality of life and illness perceptions in patients with breast cancer using a fasting mimicking diet as an adjunct to neoadjuvant chemotherapy in the phase 2 DIRECT (BOOG 2013-14) trial

9. Higher incidence rates than previously known in tenosynovial giant cell tumors

10. Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort

11. Suicidal ideation in a European Huntington's disease population

12. Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation

13. Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic Castration-Resistant Prostate Cancer

14. Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

15. Survival after recurrent osteosarcoma: Data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trials

16. Chemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells

17. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

20. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY

21. Soft tissue and visceral sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

22. Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial

23. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

24. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

25. Regarding: 'Explorative study to identify novel candidate genes related to oxaliplatin efficacy and toxicity using a DNA repair array'

28. Interferon beta-1a in relapsing multiple sclerosis: four-year extension of the European IFNbeta-1a Dose-Comparison Study

29. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications

31. [Chicken RNA tumor viruses: a model for virus-induced carcinogenesis]

33. Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet

34. PALETTE: A randomized, double-blind phase III trial of pazopanib versus placebo in patients with soft-tissue sarcoma (STS) whose disease has progressed during or following prior chemotherapy-An EORTC STBSG Global Network Study (EORTC 62072)

35. Structure and specific antigens of avian leukosis viruses

40. Electron microscopy in rapid viral diagnosis: An update

42. Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial

43. Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study

44. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study

45. Epithelioid hemangioendothelioma, an ultra-rare cancer: a consensus paper from the community of experts

46. Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network

Catalog

Books, media, physical & digital resources